JP2016534039A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534039A5
JP2016534039A5 JP2016521270A JP2016521270A JP2016534039A5 JP 2016534039 A5 JP2016534039 A5 JP 2016534039A5 JP 2016521270 A JP2016521270 A JP 2016521270A JP 2016521270 A JP2016521270 A JP 2016521270A JP 2016534039 A5 JP2016534039 A5 JP 2016534039A5
Authority
JP
Japan
Prior art keywords
composition
item
cancer
immunoconjugate
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016521270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534039A (ja
JP6463744B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/059716 external-priority patent/WO2015054400A2/en
Publication of JP2016534039A publication Critical patent/JP2016534039A/ja
Publication of JP2016534039A5 publication Critical patent/JP2016534039A5/ja
Application granted granted Critical
Publication of JP6463744B2 publication Critical patent/JP6463744B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016521270A 2013-10-08 2014-10-08 抗ｆｏｌｒ１免疫抱合体投薬レジメン Active JP6463744B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361888337P 2013-10-08 2013-10-08
US201361888365P 2013-10-08 2013-10-08
US61/888,337 2013-10-08
US61/888,365 2013-10-08
US201461948363P 2014-03-05 2014-03-05
US61/948,363 2014-03-05
US201462004815P 2014-05-29 2014-05-29
US62/004,815 2014-05-29
PCT/US2014/059716 WO2015054400A2 (en) 2013-10-08 2014-10-08 Anti-folr1 immunoconjugate dosing regimens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018208158A Division JP6581279B2 (ja) 2013-10-08 2018-11-05 抗ｆｏｌｒ１免疫抱合体投薬レジメン

Publications (3)

Publication Number Publication Date
JP2016534039A JP2016534039A (ja) 2016-11-04
JP2016534039A5 true JP2016534039A5 (enExample) 2017-11-16
JP6463744B2 JP6463744B2 (ja) 2019-02-06

Family

ID=52813740

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016521270A Active JP6463744B2 (ja) 2013-10-08 2014-10-08 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2018208158A Active JP6581279B2 (ja) 2013-10-08 2018-11-05 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2019156399A Withdrawn JP2019218386A (ja) 2013-10-08 2019-08-29 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2021125147A Active JP7386208B2 (ja) 2013-10-08 2021-07-30 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2023192883A Pending JP2024016239A (ja) 2013-10-08 2023-11-13 抗ｆｏｌｒ１免疫抱合体投薬レジメン

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018208158A Active JP6581279B2 (ja) 2013-10-08 2018-11-05 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2019156399A Withdrawn JP2019218386A (ja) 2013-10-08 2019-08-29 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2021125147A Active JP7386208B2 (ja) 2013-10-08 2021-07-30 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2023192883A Pending JP2024016239A (ja) 2013-10-08 2023-11-13 抗ｆｏｌｒ１免疫抱合体投薬レジメン

Country Status (29)

Country Link
US (3) US20150132323A1 (enExample)
EP (3) EP3055332B1 (enExample)
JP (5) JP6463744B2 (enExample)
KR (7) KR20200058592A (enExample)
CN (2) CN106164093A (enExample)
AU (4) AU2014331964C1 (enExample)
BR (1) BR112016007479A2 (enExample)
CA (1) CA2926325C (enExample)
CY (2) CY1122449T1 (enExample)
DK (2) DK3055332T3 (enExample)
ES (2) ES2759426T3 (enExample)
FI (1) FI3653228T3 (enExample)
HR (2) HRP20192140T1 (enExample)
HU (2) HUE067367T2 (enExample)
IL (4) IL313730B1 (enExample)
LT (2) LT3653228T (enExample)
MX (2) MX384973B (enExample)
MY (1) MY174670A (enExample)
NZ (2) NZ718766A (enExample)
PL (2) PL3055332T3 (enExample)
PT (2) PT3653228T (enExample)
RS (2) RS59644B1 (enExample)
RU (1) RU2696579C2 (enExample)
SG (3) SG11201602361UA (enExample)
SI (2) SI3653228T1 (enExample)
SM (1) SMT201900694T1 (enExample)
UA (1) UA119541C2 (enExample)
WO (1) WO2015054400A2 (enExample)
ZA (1) ZA201902009B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105777907B (zh) 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
ES2661466T3 (es) * 2011-04-01 2018-04-02 Immunogen, Inc. Métodos para aumentar la eficacia de la terapia contra el cáncer con FOLR1
SG11201500938XA (en) 2012-08-31 2015-04-29 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
EP2997044A4 (en) * 2013-05-14 2017-03-22 ImmunoGen, Inc. Anti-folr1 immunoconjugate dosing regimens
NZ717140A (en) 2013-08-30 2022-05-27 Immunogen Inc Antibodies and assays for detection of folate receptor 1
CN122075735A (zh) 2015-09-17 2026-05-26 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
BR112019023909A8 (pt) * 2017-05-16 2023-04-11 Immunogen Inc Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab
MA50265A (fr) 2017-09-18 2020-07-29 Sutro Biopharma Inc Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations
EP3765521A4 (en) 2018-03-13 2022-03-23 Phanes Therapeutics, Inc. ANTI-FOLATE RECEPTOR-1 ANTIBODIES AND USES THEREOF
JP7623939B2 (ja) * 2018-07-09 2025-01-29 マルチチュード インコーポレーテッド 葉酸受容体アルファに特異的な抗体
SG11202111109UA (en) 2019-04-29 2021-11-29 Immunogen Inc Biparatopic fr-alpha antibodies and immunoconjugates
KR20240017024A (ko) * 2021-06-04 2024-02-06 이뮤노젠 아이엔씨 가용성 fr-알파를 이용한 환자의 암 치료
JP2024544058A (ja) * 2021-12-01 2024-11-27 ストロ バイオファーマ インコーポレーテッド 抗葉酸受容体コンジュゲートがん治療法
CN116333135A (zh) * 2021-12-24 2023-06-27 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
IL129573A0 (en) * 1996-11-15 2000-02-29 Baxter Int Conditioning for allogeneic stem cell transplantation
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
GB0202319D0 (en) 2002-02-01 2002-03-20 Calex Electronics Ltd Apparatus
US20080131366A1 (en) * 2003-03-17 2008-06-05 Manohar Ratnam Folate Receptor Gene Modulation For Cancer Diagnosis And Therapy
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
DE602006012816D1 (de) * 2005-03-30 2010-04-22 Endocyte Inc Tifizierung von zellulären folat vitamin rezeptoren
EP1937307A4 (en) * 2005-09-14 2009-05-13 Hutchinson Fred Cancer Res SPECIFIC REMOVAL OF ACTIVATED IMMUNOCELLS
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
WO2009094456A2 (en) * 2008-01-22 2009-07-30 Johns Hopkins University Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
EP2378876B1 (en) * 2008-12-19 2018-11-14 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
MX2012004406A (es) * 2009-10-21 2012-05-08 Immunogen Inc Nuevo regimen de dosificacion y metodo de tratamiento.
CN105777907B (zh) * 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
US8530122B2 (en) 2010-07-30 2013-09-10 Konica Minolta Business Technologies, Inc. Foil transferring face forming toner and image forming method
SG189957A1 (en) * 2010-11-05 2013-06-28 Morphotek Inc Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
ES2661466T3 (es) * 2011-04-01 2018-04-02 Immunogen, Inc. Métodos para aumentar la eficacia de la terapia contra el cáncer con FOLR1
US20120282282A1 (en) * 2011-04-04 2012-11-08 Immunogen, Inc. Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates
SG11201500938XA (en) * 2012-08-31 2015-04-29 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
BR112015025424A2 (pt) * 2013-04-08 2017-07-18 Berg Llc tratamento de câncer usando terapias de combinação de coenzima q10
EP2997044A4 (en) * 2013-05-14 2017-03-22 ImmunoGen, Inc. Anti-folr1 immunoconjugate dosing regimens
NZ717140A (en) * 2013-08-30 2022-05-27 Immunogen Inc Antibodies and assays for detection of folate receptor 1
CN122075735A (zh) * 2015-09-17 2026-05-26 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合

Similar Documents

Publication Publication Date Title
JP2016520082A5 (enExample)
CA3071383C (en) Anti-cd137 antibodies
JP2021059564A (ja) 癌治療のための併用療法
JP2022058802A5 (enExample)
JP2019031568A5 (enExample)
TWI895608B (zh) 抗c-Met抗體藥物結合物
JP2011507932A5 (enExample)
JP2020508317A5 (enExample)
JP2018527383A5 (enExample)
JP2018534933A5 (enExample)
FI3394103T3 (fi) Anti-PD-1-vasta-aineiden ja bispesifisten anti-CD20-/anti-CD3-vasta-aineiden yhdistelmä syövän hoitoon
RU2018111205A (ru) Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты
EP3008093A1 (en) Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
KR20250044188A (ko) 캄프토테신계 유도체 및 리간드-약물 접합체
RU2016114708A (ru) Схемы применения иммуноконъюгата анти-folr1
KR20160138177A (ko) 항-ｅｇｆｒ 항체 및 항체 약물 접합체
IL278574B1 (en) Glycan-interacting compounds and methods of use
JP2013520442A5 (enExample)
RU2019141270A (ru) Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител
CA3093731A1 (en) Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
CA3232806A1 (en) B7-h4 antibody-drug conjugates for the treatment of cancer
JP2023534292A5 (enExample)
IL312038A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
JP2022512851A5 (enExample)
JP2024515618A (ja) 抗腫瘍処置における抗体の使用